Literature DB >> 2502417

Comparative effects of simvastatin and cholestyramine in treatment of patients with hypercholesterolaemia.

J Mölgaard1, H von Schenck, A G Olsson.   

Abstract

The efficacy and safety of 20 mg simvastatin (a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor) and of 16 g cholestyramine daily in the treatment of 34 hypercholesterolaemic patients have been compared after dietary treatment and stratified randomization. The effect of combined treatment with the two drugs was studied in 5 patients with severe hypercholesterolaemia. After 6 weeks of treatment the simvastatin group showed a significantly greater (p less than 0.05) decrease in the mean total plasma cholesterol concentration from 7.88 to 5.48 mmol/l than in the cholestyramine group in whom there was a fall from 7.82 to 6.73 mmol/l. Simvastatin decreased the mean plasma LDL cholesterol concentration from 6.07 to 3.76 mml/l and cholestyramine decreased it from 6.16 to 4.46 mmol/l. Simvastatin also reduced the mean plasma total triglycerides by 24%, VLDL triglycerides by 20% and VLDL cholesterol by 36%, while cholestyramine led to increases in these parameters by 64%, 85% and 63%, respectively. Mean plasma HDL cholesterol concentration and the subfractions HDL2 and HDL3 cholesterol were significantly increased by simvastatin. Simvastatin and cholestyramine reduced the mean plasma apolipoprotein B concentration by 28% and 13%, respectively. The mean plasma apolipoprotein A-I concentration was significantly higher only on simvastatin treatment. Simvastatin did not cause any subjective or objective side effects, while cholestyramine caused gastrointestinal problems in 31% of patients. Small increases in serum alanine aminotransferase (S-ALT) activity were seen with both drugs. Cholestyramine significantly raised the serum alkaline phosphatase (S-ALP) although to a level still within the normal range. It is concluded that 20 mg simvastatin was more effective than 16 g cholestyramine in the treatment of hypercholesterolaemia.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2502417     DOI: 10.1007/bf00558069

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Consensus conference. Lowering blood cholesterol to prevent heart disease.

Authors: 
Journal:  JAMA       Date:  1985-04-12       Impact factor: 56.272

2.  Synvinolin in hypercholesterolaemia.

Authors:  A G Olsson; J Mölgaard; H von Schenk
Journal:  Lancet       Date:  1986-08-16       Impact factor: 79.321

3.  The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.

Authors: 
Journal:  JAMA       Date:  1984-01-20       Impact factor: 56.272

4.  Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.

Authors: 
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

5.  Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth; G J Sexton
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

6.  Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.

Authors:  D R Illingworth
Journal:  Ann Intern Med       Date:  1984-11       Impact factor: 25.391

7.  Complementarity of colestipol, niacin, and lovastatin in treatment of severe familial hypercholesterolemia.

Authors:  M J Malloy; J P Kane; S T Kunitake; P Tun
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

8.  Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study.

Authors:  R J Havel; D B Hunninghake; D R Illingworth; R S Lees; E A Stein; J A Tobert; S R Bacon; J A Bolognese; P H Frost; G E Lamkin
Journal:  Ann Intern Med       Date:  1987-11       Impact factor: 25.391

9.  A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.

Authors: 
Journal:  JAMA       Date:  1988-07-15       Impact factor: 56.272

10.  Effects of simvastatin on plasma lipid, lipoprotein and apolipoprotein concentrations in hypercholesterolaemia.

Authors:  J Mölgaard; H von Schenck; A G Olsson
Journal:  Eur Heart J       Date:  1988-05       Impact factor: 29.983

View more
  5 in total

1.  Serum biochemical changes in rabbits on a regular diet with and without flax lignan complex following a high-cholesterol diet.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2008

Review 2.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 3.  Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

4.  Effects of vitamin E on serum enzymes and electrolytes in hypercholesterolemia.

Authors:  Kailash Prasad
Journal:  Mol Cell Biochem       Date:  2010-02       Impact factor: 3.396

5.  Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

Authors:  Rajesh Krishna; Amit Garg; Bo Jin; Sara Sadeghi Keshavarz; Frederick A Bieberdorf; Jeffrey Chodakewitz; John A Wagner
Journal:  Br J Clin Pharmacol       Date:  2009-02-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.